Loading...
Market
What will cause a delay in Catalent acquisition finalization by 2024 end?
2
Resolution / Starting Odds
Regulatory issues • 25%
Financial issues • 25%
Operational challenges • 25%
No delay • 25%
Official statements from Novo Nordisk or Catalent, or credible news reports
Story
Novo Nordisk to Finalize $16.5 Billion Catalent Acquisition of Three Manufacturing Sites After FTC Approval
Dec 14, 2024, 03:45 PM
Novo Nordisk is poised to finalize its acquisition of three manufacturing sites from Catalent, following the Federal Trade Commission's (FTC) decision not to challenge the $16.5 billion acquisition by Novo Holdings of Catalent. This acquisition is expected to bolster Novo Nordisk's production capabilities, particularly in response to the growing demand for its anti-obesity drugs, including Wegovy and Ozempic. The deal has cleared all regulatory closing conditions, allowing Novo Nordisk to proceed with its plans to enhance its manufacturing capacity. The acquisition is strategically significant as Catalent is a key subcontractor in the production of Wegovy, which has seen increased demand due to its popularity in treating obesity.
View original story
Similar markets
Regulatory hurdles • 25%
Financing issues • 25%
Shareholder opposition • 25%
Other • 25%
Regulatory approval issues • 25%
Financing difficulties • 25%
Legal challenges • 25%
Other • 25%
Approve without conditions • 25%
Approve with conditions • 25%
Block the acquisition • 25%
Extend review period • 25%
Regulatory issues • 25%
Shareholder opposition • 25%
Financing issues • 25%
Other • 25%
Antitrust Concerns • 25%
Financial Discrepancies • 25%
Intellectual Property Issues • 25%
Other • 25%
Yes • 50%
No • 50%
Regulatory issues • 25%
Shareholder disapproval • 25%
Financial constraints • 25%
Other reasons • 25%
Manufacturing issues • 25%
Regulatory hurdles • 25%
Supply chain disruptions • 25%
Other • 25%